Director/PDMR Shareholding


(MENAFN- GlobeNewsWire - Nasdaq) DXS INTERNATIONAL PLC

(AQSE: DXSP)

Notification of Director / PDMR Dealing

DXS INTERNATIONAL PLC

The Board of DXS International plc (the“Company” or“DXSP), the AQSE Growth market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 30 October 2024 Mr Bob Sutcliffe, the Chairman, purchased a total of 50,000 Ordinary Shares in the Company at a price of 1.0p per share. Further, today 31 October 2024, Mr Bob Sutcliffe purchased a total of 133,333 Ordinary Shares in the Company at a price of 1.5p per share

Following this transaction Mr Sutcliffe and his wife's interest in DXS Ordinary Shares is 1,116,719 Ordinary Shares representing 1.74% of the issued share capital of the Company.

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mr. Robert Sutcliffe
2 Reason for the notification
a)
Position/status
Chairman
b)
Initial notification /Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name

DXS INTERNATIONAL PLC
b)
LEI

2138001R1KEUWTXEVJ44
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)






Description of the financial instrument, type of instrument Ordinary Shares of 0.33p each
Identification code ISIN GB00B2Q6HZ92
b)
Nature of the transaction
Purchase of shares
c)






Price(s) and volume(s)
Price(s) Volume(s)
1.0p 50,000
1.5p 133,333
d)










Aggregated information
- Aggregated volume
- Price
e)
Date of the transaction

30 October 2024 and 31 October 2024
f)
Place of the transaction

Aquis Stock Exchange

The Directors of DXS International plc accept responsibility for this announcement.

Contacts:

David Immelman
DXS International plc
01252 719800
AQSE Corporate Broker and Corporate Advisor
Hybridan LLP
Claire Louise Noyce
020 3764 2341

Notes to Editors

About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.


MENAFN31102024004107003653ID1108838621


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.